港股异动 | 康希诺生物(06185)再涨近6% 24价肺炎球菌多糖结合疫苗获批进入临床试验

智通财经01-07

智通财经APP获悉，康希诺生物(06185)再涨近6%，截至发稿，涨4.02%，报38.8港元，成交额3009.75万港元。消息面上，康希诺生物发布公告，公司自主研发的24价肺炎球菌多糖结合疫苗（CRM197/破伤风类毒素，简称“PCV24”）正式获得国家药品监督管理局签发的《药物临床试验批准通知书》，获准开展临床试验。截至公告披露日，国内外市场上尚无24价肺炎球菌结合疫苗上市产品。根据公告，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2601823815?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-07 11:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601823815","market":"fut","top_or_hot":-1,"title":"港股异动 | 康希诺生物(06185)再涨近6% 24价肺炎球菌多糖结合疫苗获批进入临床试验","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，康希诺生物(06185)再涨近6%，截至发稿，涨4.02%，报38.8港元，成交额3009.75万港元。消息面上，康希诺生物发布公告，公司自主研发的24价肺炎球菌多糖结合疫苗（CRM197/破伤风类毒素，简称“PCV24”）正式获得国家药品监督管理局签发的《药物临床试验批准通知书》，获准开展临床试验。截至公告披露日，国内外市场上尚无24价肺炎球菌结合疫苗上市产品。根据公告，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1389683.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 康希诺生物(06185)再涨近6% 24价肺炎球菌多糖结合疫苗获批进入临床试验</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 康希诺生物(06185)再涨近6% 24价肺炎球菌多糖结合疫苗获批进入临床试验\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-07 11:04 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1389683.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，康希诺生物(06185)再涨近6%，截至发稿，涨4.02%，报38.8港元，成交额3009.75万港元。消息面上，康希诺生物发布公告，公司自主研发的24价肺炎球菌多糖结合疫苗（CRM197/破伤风类毒素，简称“PCV24”）正式获得国家药品监督管理局签发的《药物临床试验批准通知书》，获准开展临床试验。截至公告披露日，国内外市场上尚无24价肺炎球菌结合疫苗上市产品。根据公告，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1389683.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1389683.html","article_id":"2601823815","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601823815","pubTimestamp":1767755058,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"消息面上，康希诺生物发布公告，公司自主研发的24价肺炎球菌多糖结合疫苗正式获得国家药品监督管理局签发的《药物临床试验批准通知书》，获准开展临床试验。截至公告披露日，国内外市场上尚无24价肺炎球菌结合疫苗上市产品。PCV24是公司在已有技术积累的基础上，进一步推进的高价次肺炎球菌结合疫苗研发。公司表示，此次获批进一步丰富和完善了公司在肺炎球菌结合疫苗领域的研发管线。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159646":"疫苗","BK1161":"生物科技","BK1191":"制药","BK1515":"抗疫概念","06185":"康希诺生物","BK1574":"生物医药B类股"},"translate_title":"Changes in Hong Kong stocks | CanSino Biologics (06185) rose nearly 6%, 24-valent pneumococcal polysaccharide conjugate vaccine was approved to enter clinical trials","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159646":1.5,"06185":1.5},"content_text":"智通财经APP获悉，康希诺生物(06185)再涨近6%，截至发稿，涨4.02%，报38.8港元，成交额3009.75万港元。消息面上，康希诺生物发布公告，公司自主研发的24价肺炎球菌多糖结合疫苗（CRM197/破伤风类毒素，简称“PCV24”）正式获得国家药品监督管理局签发的《药物临床试验批准通知书》，获准开展临床试验。截至公告披露日，国内外市场上尚无24价肺炎球菌结合疫苗上市产品。根据公告，PCV24完成了24种血清型纯化多糖、多糖蛋白结合物原液生产工艺、成品处方的开发和确认，覆盖当前肺炎球菌主要流行血清型，并采用多糖抗原与蛋白载体共价结合的方式以及双载体技术，拟适用于2月龄（最小6周）及以上人群接种，以预防由 24 种肺炎球菌血清型引起的感染性疾病。PCV24是公司在已有技术积累的基础上，进一步推进的高价次肺炎球菌结合疫苗研发。公司表示，此次获批进一步丰富和完善了公司在肺炎球菌结合疫苗领域的研发管线。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2601823815","isCrawlerRequest":true}